financetom
Business
financetom
/
Business
/
Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit
Jul 25, 2024 12:19 PM

July 25 (Reuters) - Monsanto will pay $160 million to

settle a lawsuit by the city of Seattle that accused the unit of

Germany's Bayer of polluting the city's drainage

system and the local Lower Duwamish River with toxic chemicals

known as PCBs.

City Attorney Ann Davison announced the settlement on

Thursday, calling it the largest for a single city over PCB

pollution.

In a statement, Monsanto said it will pay $35 million for

PCB remediation, and $125 million to address other Seattle

claims. The company did not admit liability or wrongdoing.

Seattle accused Monsanto of creating a public nuisance by

selling polychlorinated biphenyls for commercial use from 1935

to 1977 despite knowing they polluted the environment, harming

people and wildlife.

The city said PCBs remained over the years in exterior paint

and caulk on buildings, and resulted in contaminated stormwater

flowing into the river.

Seattle sued Monsanto in January 2016. The settlement averts

a scheduled Sept. 23 trial in that city's federal court.

Monsanto said in an August 2022 filing that Seattle had been

seeking nearly $750 million.

The company reached a separate $95 million settlement with

Washington state in June 2020 over PCB contamination.

PCBs were outlawed by the U.S. government in 1979, and have

been linked to cancer, immune system and other health problems.

Monsanto was the only U.S. maker of PCBs. It has said it

stopped making them because they were not readily biodegradable.

In November 2022, Monsanto won court approval for a $650

million settlement with a class of 2,500 local governments over

PCB contamination in various waters.

Other governments chose to sue Monsanto individually.

Monsanto said nine cases remain pending, and that it is

committed to defending itself at trial unless it settles.

Bayer bought Monsanto for $63 billion in 2018. It has also

faced extensive and costly litigation over whether Monsanto's

Roundup weed killer causes cancer.

The case is Seattle v. Monsanto Co et al, U.S. District

Court, Western District of Washington, No. 16-00107.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
3M, HD Hyundai Korea Shipbuilding & Marine Engineering to Partner on Research for Liquid Hydrogen Storage Tanks
3M, HD Hyundai Korea Shipbuilding & Marine Engineering to Partner on Research for Liquid Hydrogen Storage Tanks
Mar 7, 2024
01:20 PM EST, 03/07/2024 (MT Newswires) -- 3M ( MMM ) agreed with HD Hyundai Korea Shipbuilding & Marine Engineering on a joint research project to develop large liquid hydrogen storage tanks using the conglomerate's glass bubbles insulation system. This collaboration is a major step forward in the pursuit of making hydrogen technologies available at scale, 3M Advanced Materials Division...
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
Mar 7, 2024
01:25 PM EST, 03/07/2024 (MT Newswires) -- Marinus Pharmaceuticals' ( MRNS ) Ztalmy was approved by the UK Medicines and Healthcare products Regulatory Agency on Thursday for the treatment of seizures in patients with cyclin-dependent kinase-like 5 deficiency disorder. Ztalmy, or ganaxolone, is the first anti-seizure medication approved for the treatment of this rare genetic disorder in the UK, according...
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Mar 7, 2024
Thursday, Creative Medical Technology Holdings Inc ( CELZ ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals. The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.  This personalized medicine approach focuses on a single...
Cellebrite Launches FedRAMP Authorization Process for SaaS Offerings
Cellebrite Launches FedRAMP Authorization Process for SaaS Offerings
Mar 7, 2024
01:20 PM EST, 03/07/2024 (MT Newswires) -- Cellebrite DI ( CLBT ) said Thursday it has launched the process to seek Federal Risk and Authorization Management Program, or FedRAMP, authorization for its software-as-a-service offerings. The company said it has enlisted cybersecurity firm Coalfire to assist in the activities required to complete the process within the next 12 months. FedRAMP authorization...
Copyright 2023-2026 - www.financetom.com All Rights Reserved